SEARCH

SEARCH BY CITATION

References

  • 1
    World Tourism Organization (UNWTO). Tourism highlights. 2012 edition. Available at: http://mkt.unwto.org/en/content/tourismhighlights. (Accessed 2013 May 13).
  • 2
    Ljungman P. Vaccination of immunocompromised patients. Clin Microbiol Infect 2012; 18(Suppl 5):9399.
  • 3
    Schrauder A, Henke-Gendo C, Seidemann K, et al. Varicella vaccination in a child with acute lymphoblastic leukaemia. Lancet 2007; 369:1232.
  • 4
    Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 2002; 85:131134.
  • 5
    Patel NC, Hertel PM, Estes MK, et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N Engl J Med 2010; 362:314319.
  • 6
    Van den Bijllaardt W, Siers HM, Timmerman-Kok C, et al. Seroprotection after hepatitis a vaccination in patients with drug-induced immunosuppression. J Travel Med 2013; 20:278282.
  • 7
    Launay O, Grabar S, Gordien E, et al. HEPAVAC Study Group. Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study. J Acquir Immune Defic Syndr 2008; 49:272275.
  • 8
    Eckerle I, Rosenberger KD, Zwahlen M, Junghanss T. Serologic vaccination response after solid organ transplantation: a systematic review. PLoS One 2013; 8:e56974.
  • 9
    Bovier PA. Epaxal: a virosomal vaccine to prevent hepatitis A infection. Expert Rev Vaccines 2008; 7:11411150.
  • 10
    Saksawad R, Likitnukul S, Warachit B, et al. Immunogenicity and safety of a pediatric dose virosomal hepatitis A vaccine in Thai HIV-infected children. Vaccine 2011; 29(29–30):47354738.
  • 11
    Jentes ES, Poumerol G, Gershman MD, et al., Informal WHO Working Group on Geographic Risk for Yellow Fever. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis 2011; 11:622632 Erratum in: Lancet Infect Dis. 2012;12(2):98.
  • 12
    Staples JE, Gershman M, Fischer M, Centers for Disease Control and Prevention (CDC). Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59(RR-7):127.
  • 13
    Mota LM, Oliveira AC, Lima RA, et al. Vaccination against yellow fever among patients on immunosuppressors with diagnoses of rheumatic diseases. Rev Soc Bras Med Trop 2009; 42:2327.
  • 14
    Scheinberg M, Guedes-Barbosa LS, Mangueira C, et al. Yellow fever revaccination during infliximab therapy. Arthritis Care Res (Hoboken) 2010; 62:896898.
  • 15
    Le calendrier des vaccinations et les recommandations vaccinales 2013 selon l'avis du Haut Conseil de la santé publique. Bulletin Epidémiologique Hebdomadaire 19 avril 2013/n°14-15:129–158.
  • 16
    The British Society for Rheumatology. Vaccinations in the immunocompromised person. Guidelines for the patient taking immunosuppressant, steroids and the new biologic therapies. 2002. Available at: http://www.rheumatology.org.uk/includes/documents/cm_docs/2009/v/vaccinations_in_the_immunocompromised_person.pdf. (Accessed 2013 July 3)
  • 17
    Kernéis S, Launay O, Ancelle T, et al. Safety and immunogenicity of yellow fever 17D vaccine in adults receiving systemic corticosteroid therapy: an observational cohort study. Arthritis Care Res (Hoboken). doi: 10.1002/acr.22021 [Epub ahead of print].